Search

Changning M Yan

age ~56

from Houston, TX

Get Report
Also known as:
  • Changnin Yan
  • Chang M Yan
  • Cheng Yan
  • Ning Yan Chang
  • Yan Changning
  • Judy Y Chang
  • Chang Y An
  • Yan Chang
  • Yuan Chang
  • Yan Cheng
Phone and address:
1800 El Paseo St, Houston, TX 77054
7137900321
Related to:
Connected to:

Changning Yan Phones & Addresses

  • 1800 El Paseo St, Houston, TX 77054 • 7137900321
  • 1800 El Paseo St APT 306, Houston, TX 77054
  • 4041 Drake St APT 111, Houston, TX 77005
  • Webster, TX
  • Pearland, TX
  • Galveston, TX
  • Humble, TX

Us Patents

  • Anti-Il 13 Antibodies And Uses Thereof

    view source
  • US Patent:
    8088618, Jan 3, 2012
  • Filed:
    Sep 29, 2008
  • Appl. No.:
    12/240604
  • Inventors:
    Sek Chung Fung - Gaithersburg MD, US
    Matthew Moyle - Redmond WA, US
    Mason Lu - Houston TX, US
    Changning Yan - Houston TX, US
    Sanjaya Singh - Sandy Hook CT, US
    Dan Huang - Short Hills NJ, US
  • Assignee:
    Genentech, Inc. - South San Francisco CA
  • International Classification:
    C12N 5/10
    C07K 16/24
  • US Classification:
    435335, 530350, 5303871, 5303873, 53038823, 5303891, 5303892, 5303913
  • Abstract:
    The present invention relates to anti-IL13 antibodies that bind specifically and with high affinity to both glycosylated and non-glycosylated human IL13, does not bind mouse IL13, and neutralize human IL13 activity at an approximate molar ratio of 1:2 (MAb:IL13). The invention also relates to the use of these antibodies in the treatment of IL13-mediated diseases, such as allergic disease, including asthma, allergic asthma, non-allergic (intrinsic) asthma, allergic rhinitis, atopic dermatitis, allergic conjunctivitis, eczema, urticaria, food allergies, chronic obstructive pulmonary disease, ulcerative colitis, RSV infection, uveitis, scleroderma, and osteoporosis.

  • Novel Anti-Il13 Antibodies And Uses Thereof

    view source
  • US Patent:
    20090214523, Aug 27, 2009
  • Filed:
    Dec 23, 2004
  • Appl. No.:
    10/583927
  • Inventors:
    Sek Chung Fung - Gaithersburg MD, US
    Matthew Moyle - Redmond WA, US
    Mason Lu - Houston TX, US
    Changning Yan - Houston TX, US
    Sanjaya Singh - Sandy Hook CT, US
    Dan Huang - Short Hills NY, US
  • Assignee:
    Genentech, Inc. - San Francisco CA
  • International Classification:
    A61K 39/395
    C07K 16/24
  • US Classification:
    4241331, 5303879, 5303873, 4241391
  • Abstract:
    The present invention relates to anti-IL13 antibodies that bind specifically and with high affinity to both glycosylated and non-glycosylated human IL13, does not bind mouse IL13, and neutralize human IL13 activity at an approximate molar ratio of 1:2 (MAb:IL13). The invention also relates to the use of these antibodies in the treatment of IL13-mediated diseases, such as allergic disease, including asthma, allergic asthma, non-allergic (intrinsic) asthma, allergic rhinitis, atopic dermatitis, allergic conjunctivitis, eczema, urticaria, food allergies, chronic obstructive pulmonary disease, ulcerative colitis, RSV infection, uveitis, scleroderma, and osteoporosis.

  • Novel Anti-Il13 Antibodies And Uses Thereof

    view source
  • US Patent:
    20120156203, Jun 21, 2012
  • Filed:
    Oct 18, 2011
  • Appl. No.:
    13/275684
  • Inventors:
    Sek Chung Fung - Gaithersburg MD, US
    Matthew Moyle - Redmond WA, US
    Mason Lu - Houston MA, US
    Changning Yan - Houston TX, US
    Sanjaya Singh - Sandy Hook CT, US
    Dan Huang - Short Hills NJ, US
  • International Classification:
    A61K 39/395
    A61P 11/00
    A61P 29/00
  • US Classification:
    4241351, 4241331, 4241361, 4241421, 4241451, 4241781
  • Abstract:
    The present invention relates to anti-IL13 antibodies that bind specifically and with high affinity to both glycosylated and non-glycosylated human IL13, does not bind mouse IL13, and neutralize human IL13 activity at an approximate molar ratio of 1:2 (MAb:IL13). The invention also relates to the use of these antibodies in the treatment of IL13-mediated diseases, such as allergic disease, including asthma, allergic asthma, non-allergic (intrinsic) asthma, allergic rhinitis, atopic dermatitis, allergic conjunctivitis, eczema, urticaria, food allergies, chronic obstructive pulmonary disease, ulcerative colitis, RSV infection, uveitis, scleroderma, and osteoporosis.

  • Novel Anti-Il13 Antibodies And Uses Thereof

    view source
  • US Patent:
    20120164144, Jun 28, 2012
  • Filed:
    Oct 18, 2011
  • Appl. No.:
    13/275658
  • Inventors:
    Sek Chung Fung - Gaithersburg MD, US
    Matthew Moyle - Redmond WA, US
    Mason Lu - Houston TX, US
    Changning Yan - Houston TX, US
    Sanjaya Singh - Sandy Hook CT, US
    Dan Huang - Short Hills NJ, US
  • International Classification:
    A61K 39/395
    A61P 37/08
    A61P 11/06
  • US Classification:
    4241351, 4241451, 4241331, 4241361, 4241781
  • Abstract:
    The present invention relates to anti-IL13 antibodies that bind specifically and with high affinity to both glycosylated and non-glycosylated human IL13, does not bind mouse IL13, and neutralize human IL13 activity at an approximate molar ratio of 1:2 (MAb:IL13). The invention also relates to the use of these antibodies in the treatment of IL13-mediated diseases, such as allergic disease, including asthma, allergic asthma, non-allergic (intrinsic) asthma, allergic rhinitis, atopic dermatitis, allergic conjunctivitis, eczema, urticaria, food allergies, chronic obstructive pulmonary disease, ulcerative colitis, RSV infection, uveitis, scleroderma, and osteoporosis.

  • Novel Anti-Il13 Antibodies And Uses Thereof

    view source
  • US Patent:
    20120214971, Aug 23, 2012
  • Filed:
    Nov 30, 2011
  • Appl. No.:
    13/308186
  • Inventors:
    Sek Chung Fung - Gaithersburg MD, US
    Matthew Moyle - Redmond WA, US
    Mason Lu - Houston TX, US
    Changning Yan - Houston TX, US
    Sanjaya Singh - Sandy Hook CT, US
    Dan Huang - Short Hills NJ, US
  • International Classification:
    C07K 16/24
    C07K 16/46
  • US Classification:
    5303873, 5303892, 5303879, 53038823
  • Abstract:
    The present invention relates to anti-IL13 antibodies that bind specifically and with high affinity to both glycosylated and non-glycosylated human IL13, does not bind mouse IL13, and neutralize human IL13 activity at an approximate molar ratio of 1:2 (MAb:IL13). The invention also relates to the use of these antibodies in the treatment of IL13-mediated diseases, such as allergic disease, including asthma, allergic asthma, non-allergic (intrinsic) asthma, allergic rhinitis, atopic dermatitis, allergic conjunctivitis, eczema, urticaria, food allergies, chronic obstructive pulmonary disease, ulcerative colitis, RSV infection, uveitis, scleroderma, and osteoporosis.

  • Novel Anti-Il13 Antibodies And Uses Thereof

    view source
  • US Patent:
    20200291106, Sep 17, 2020
  • Filed:
    Nov 13, 2019
  • Appl. No.:
    16/682773
  • Inventors:
    - South San Francisco CA, US
    Matthew MOYLE - Redmond WA, US
    Mason LU - Houston TX, US
    Changning YAN - Houston TX, US
    Sanjaya SINGH - Sandy Hook CT, US
    Dan HUANG - Short Hills NJ, US
  • Assignee:
    Genentech, Inc. - South San Francisco CA
  • International Classification:
    C07K 16/24
  • Abstract:
    The present invention relates to anti-IL13 antibodies that bind specifically and with high affinity to both glycosylated and non-glycosylated human IL13, does not bind mouse IL13, and neutralize human IL13 activity at an approximate molar ratio of 1:2 (MAb:IL13). The invention also relates to the use of these antibodies in the treatment of IL13-mediated diseases, such as allergic disease, including asthma, allergic asthma, non-allergic (intrinsic) asthma, allergic rhinitis, atopic dermatitis, allergic conjunctivitis, eczema, urticaria, food allergies, chronic obstructive pulmonary disease, ulcerative colitis, RSV infection, uveitis, scleroderma, and osteoporosis.

  • Novel Anti-Il13 Antibodies And Uses Thereof

    view source
  • US Patent:
    20180251538, Sep 6, 2018
  • Filed:
    Sep 29, 2017
  • Appl. No.:
    15/721570
  • Inventors:
    - South San Francisco CA, US
    Matthew MOYLE - Redmond WA, US
    Mason LU - Houston TX, US
    Changning YAN - Houston TX, US
    Sanjaya SINGH - Sandy Hook CT, US
    Dan Huang - Short Hills NJ, US
  • International Classification:
    C07K 16/24
    A61K 39/00
  • Abstract:
    The present invention relates to anti-IL13 antibodies that bind specifically and with high affinity to both glycosylated and non-glycosylated human IL13, does not bind mouse IL13, and neutralize human IL13 activity at an approximate molar ratio of 1:2 (MAb:IL13). The invention also relates to the use of these antibodies in the treatment of IL13-mediated diseases, such as allergic disease, including asthma, allergic asthma, non-allergic (intrinsic) asthma, allergic rhinitis, atopic dermatitis, allergic conjunctivitis, eczema, urticaria, food allergies, chronic obstructive pulmonary disease, ulcerative colitis, RSV infection, uveitis, scleroderma, and osteoporosis.

  • Novel Anti-Il13 Antibodies And Uses Thereof

    view source
  • US Patent:
    20140105897, Apr 17, 2014
  • Filed:
    Aug 20, 2013
  • Appl. No.:
    13/971394
  • Inventors:
    - San Fransisco CA, US
    Matthew Moyle - Redmond WA, US
    Mason Lu - Houston TX, US
    Changning Yan - Houston TX, US
    Sanjaya Singh - Sandy Hook CT, US
    Dan Huang - Short Hills NJ, US
  • Assignee:
    Genentech, Inc. - San Fransisco CA
  • International Classification:
    C07K 16/24
  • US Classification:
    4241351, 4241331, 4241361, 4241451, 4241781
  • Abstract:
    The present invention relates to anti-IL13 antibodies that bind specifically and with high affinity to both glycosylated and non-glycosylated human IL13, does not bind mouse IL13, and neutralize human IL13 activity at an approximate molar ratio of 1:2 (MAb:IL13). The invention also relates to the use of these antibodies in the treatment of IL13-mediated diseases, such as allergic disease, including asthma, allergic asthma, non-allergic (intrinsic) asthma, allergic rhinitis, atopic dermatitis, allergic conjunctivitis, eczema, urticaria, food allergies, chronic obstructive pulmonary disease, ulcerative colitis, RSV infection, uveitis, scleroderma, and osteoporosis.

Youtube

Su yan is learning how to perform face changi...

Su yan is learning how to perform face changing wo...

The news conference of the drama"Putting Down Bandits in Kawanishi " w...

  • Category:
    Entertainment
  • Uploaded:
    11 Jun, 2012
  • Duration:
    1m 41s
Get Report for Changning M Yan from Houston, TX, age ~56
Control profile